Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huxin Jiaonang is a traditional Chinese medicine (TCM) developed and manufactured by Guangzhou Baiyunshan Qixing Pharmaceutical. It is an oral capsule formulation primarily indicated for the treatment of cardiovascular diseases, specifically coronary heart disease and angina pectoris. The preparation is designed to invigorate Qi, nourish Yin, and promote blood circulation to resolve blood stasis. Its pharmacological profile includes the dilation of coronary arteries, improvement of myocardial blood supply, reduction of myocardial oxygen consumption, and inhibition of platelet aggregation. It is commonly prescribed in China for patients experiencing stable angina and other symptoms related to myocardial ischemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huxin jiaonang.